The webcast, as with other selected presentations regarding developments in
About
More than 45 years ago,
For more information, visit Amgen.com and follow
CONTACT:
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2026-virtual-oncology-leadership-summit-302687989.html
SOURCE
United States (US) indices fell sharply, with the Dow Jones down 1.34%, the S&P 500 losing 1.57% and the Nasdaq 100 sliding 2.04% as investors accelerated their rotation out of technology and other risk-sensitive sectors.
Cisco plunged 12.3% after missing on adjusted gross margin, its worst one-day drop since 2022, weighing on mega caps including Apple, NVIDIA, Broadcom and Amazon and reigniting concerns over the returns on heavy AI-driven spending.
The Dow transports index slid 4% on fears around artificial intelligence (AI)-led automation, while HP and Dell fell after Lenovo warned of shipment pressure linked to memory-chip shortages.
Investors shifted into utilities, consumer staples and real estate, while US Treasury yields dropped sharply, with the 10-year yield down 7bp as strong demand at a 30-year auction supported bonds.
MSCI’s Asia-Pacific index fell 1.1%, Japan’s Nikkei 225 dropped 1.3% and Hong Kong’s Hang Seng slid 2.1%, tracking Wall Street’s tech-led declines, while US futures edged lower ahead of the European open.
Weekly jobless claims fell by less than expected and markets now await January consumer price index (CPI), with core prices forecast to rise 0.3% month-on-month (MoM) and annual core inflation seen easing to 2.5%, as traders price around 60bp of Federal Reserve (Fed) cuts this year.
The recent S&P 500 rally ran out of steam marginally below its 7002 late January record high and rapidly slid back towards support at the early January 6824 low.
A fall through this level seems to be on the cards now with the November to February support line and 20 January-to-early February lows at 6807 – 6780 being on the cards.
Were this support zone to give way, the December trough at 6720 would be in sight.
Resistance may now be spotted around the 29 January low at 6871.
Chambers Global 2026 has recognized Goodwin lawyers and practices for excellence in geographies around the world. Goodwin received 43 lawyer rankings and 38 practice rankings—both firm records—in this year’s edition of the guide.
Clients noted that the Goodwin team is “innovative, well informed, entrepreneurial and knowledgeable” and is an “excellent resource across legal areas, extremely responsive and extremely well connected to the market.”
Chambers Global recognized the following Goodwin practices as leaders in the international market:
Asia-Pacific Region
China
France
Germany
Global
India
Israel
United Kingdom
United States
Goodwin lawyers were also ranked as leading lawyers in their fields, including:
Belgium
China
France
Germany
India
Luxembourg
United Kingdom
United States
Elon Musk’s artificial intelligence company is continuing to fuel its datacenters with unpermitted gas turbines, an investigation by the Floodlight newsroom shows. Thermal footage captured by Floodlight via drone shows xAI is still burning gas at a facility in Southaven, Mississippi, despite a recent Environmental Protection Agency (EPA) ruling reiterating that doing so requires a state permit in advance.
State regulators in Mississippi maintain that since the turbines are parked on tractor trailers, they don’t require permits. However, the EPA has long required that such pollution sources be permitted under the Clean Air Act.
Any exemption for these machines “could leave these engines subject to no emission standards at all”, the agency wrote in a January final ruling.
However, thermal images captured by Floodlight – and analyzed by multiple experts – show more than a dozen unpermitted turbines still spewing pollutants at the plant nearly two weeks after the EPA’s recent ruling.
“That is a violation of the law,” said Bruce Buckheit, a former EPA air enforcement chief, after reviewing Floodlight’s images and EPA regulations. “You’re supposed to get permission first.”
xAI, which is seeking permits for dozens more turbines in Southaven, did not respond to multiple requests for comment. The EPA, which under Trump has initiated a record-low number of enforcement actions, declined to answer questions about the turbines at Musk’s AI facilities and referred to local authorities on permits.
The first and only public hearing on the matter is scheduled for Tuesday 17 February, and the public comment period is still open.
The Trump administration has made AI a priority, but as datacenters proliferate across the country, regulators are struggling to keep pace with the industry’s increasing reliance on custom-built or ad hoc power sources and their public health impacts on surrounding communities. And Southaven, where state regulators are at odds with federal guidance, is a prime example.
The turbines there help power Grok, the company’s controversial chatbot, and emit harmful pollutants linked to health problems such as asthma, lung cancer and heart attacks.
“The risk of living next to this type of power plant is well documented,” said Shaolei Ren, a UC Riverside associate professor who specializes in the health impacts of datacenters. “From the health perspective, we know that this is not good.”
Southaven residents have voiced concerns for months about the noise and pollution emanating from the 114-acre site that is largely hidden from public view – a site xAI is looking to expand.
“For them to be releasing so much pollution in such a populated area, not to mention that there are at least 10 schools within a two-mile radius of the facility, is really concerning,” said longtime resident Shannon Samsa. “It’s horrifying to me that we’re allowing this in our community.”
The Southaven turbine cluster is part of xAi’s rapidly growing footprint along the Tennessee-Mississippi border. That expansion began in the spring of 2024 in South Memphis, next to historically Black neighborhoods, which often disproportionately bear the brunt of pollution from nearby plants, with the construction of Colossus 1, which the company touted as the world’s largest AI supercomputer.
The Southern Environmental Law Center (SELC) released thermal images in April revealing that xAi had been operating more than 30 unpermitted gas-powered turbines at that site.
“We were hopeful that the health department would step in,” said Patrick Anderson, a senior attorney at the SELC. “That never happened.”
County officials in Tennessee maintained that the turbines did not require a permit despite longstanding EPA policy that they do. In July, amid local pushback, the county permitted 15 turbines for use at the Colossus 1 site.
On 15 January, the EPA reiterated its decades-old policy that such machines need a permit. By then, xAi had already built a second datacenter in the area, Colossus 2. To power it, the company parked 27 turbines just across the state line in Southaven, Mississippi, a diverse Memphis suburb with higher than average levels of air pollution.
“When you’re talking about these turbines, think of the jet engine,” said Buckheit.
Despite the EPA’s recent directive, Floodlight’s thermal imagery – analyzed by multiple experts – shows 15 unpermitted turbines in operation at the Southaven facility. Public records obtained by Floodlight show 18 of the 27 turbines have been used since November, at least.
“One might easily have expected, since this has been going on for some months, at least a stop-work order [issued from the EPA],” said Buckheit, who served during the Republican Gerald Ford and George W Bush administrations. He also said the EPA could refer the case to the Department of Justice.
“But apparently that didn’t happen.”
An EPA spokesperson did not answer Floodlight’s questions relating to its enforcement options, instead saying: “EPA does not approve the operation of gas turbines at facilities, that would be the state or local air permitting authority.”
Indeed, air permits are traditionally handled by state agencies. However, according to its own website, the EPA is responsible for making sure these agencies comply with federal regulations, and “generally will take enforcement action” if a state government fails to “take timely and appropriate action”.
xAI “violated the Clean Air Act the first time, and now they’re gonna copy and paste and do it again”, said the SELC’s Anderson. “I maybe had some naive hope that the regulators who are most in the day-to-day business of implementing the Clean Air Act in Mississippi would do the right thing.”
In response to Floodlight’s questions, a spokesperson from the Mississippi department of environmental quality said the EPA’s recent rule leaves permitting decisions to state authorities.
“The turbines currently operating at the Southaven facility are classified as portable/mobile units under state law and therefore remain exempt from air permitting requirements during this temporary period,” they said. “Nothing in the EPA’s January 15 rule altered that determination under Mississippi regulations.”
Longtime resident Krystal Polk said she had no idea xAI was coming to Southaven until black fences were set up across the street from her house. The area, she said, was once quiet and serene, with an abundance of wildlife, but is now bombarded by ceaseless noise and pollution.
“I do feel like xAi is playing by a different set of rules,” she said.
Polk, who has asthma, said she was forced to empty out the home that’s been in her family for generations and cancel her plans to retire there out of concerns for her health.
“We are a casualty of the whole datacenter race,” she said. “I feel that my voice doesn’t matter.”
The spokesperson for the Mississippi department of environmental quality said the agency takes public concern about emissions, noise and overall quality of life seriously, and though the turbines – in the department’s view – do not require permits, all “applicable air quality standards still apply”.
Despite lofty sustainability goals put forward by industry leaders, datacenters across the country are increasingly turning to fossil fuels to power the AI boom by using custom-built power plants like the ones seen in Southaven.
Roughly 75% of this power comes from natural gas, according to a recent report by Cleanview, which tracks clean energy and datacenter projects.
“Nearly every project we reviewed mentions renewables, hydrogen, or nuclear in its public announcements,” the author wrote, but renewables aren’t scheduled until 2028 or later.
And “nuclear is a decade away”, he said.
Now xAI is seeking to expand in Southaven, applying in January for a permit to operate 41 turbines at the site.
The facility could emit more than 6m tons of greenhouse gases and more than 1,300 tons of health-harming air pollutants every year, according to xAI’s permit application. That would make it among the largest fossil fuel power plants in the state. The company also bought property in Southaven for a third datacenter that, when completed, will make the Colossus cluster – spanning Memphis to Southaven – one of the largest datacenter complexes in the world.
“It would be devastating,” said Samsa, the Southaven resident. “No community in their right mind would want something like this in their back yards.”
Samsa, a physician’s assistant, had hoped to raise a family in Southaven, but the presence of xAi’s gas-powered turbines has made her and her husband reconsider. She has helped collect more than 1,000 signatures for a petition demanding Mississippi authorities shut down the plant.
“I don’t want my children to be growing up around such massive amounts of air pollution,” she said. “I don’t want them to have to live in a place where their health and their overall wellbeing is not considered over economics.”
Cocoa prices have fallen nearly 70% since last Valentine’s Day, but that won’t make heart-shaped boxes of chocolate or even chocolate Easter bunnies more affordable this year.
Chocolate prices at U.S. retail stores rose 14% between Jan. 1 and the first week of February compared to the same period last year, according to market research company Datasembly. That’s on top of a 7.8% increase for the same period in 2025.
WATCH: Hard-hit cocoa harvests in West Africa cause chocolate prices to soar worldwide
Europe has seen even steeper price increases. In Germany, chocolate prices rose 18.9% in 2025, according to government figures.
Here’s what caused the price of cocoa futures to rise and then fall — and why that may not be reflected in the prices customers are paying.
A cocoa farmer sun-dries cocoa beans at his home in Zambolee, Central Region, Ghana, on Feb. 10, 2026. Photo by Francis Kokoroko/ Reuters
Cocoa prices more than doubled in 2024 due to insufficient rainfall and crop diseases in West Africa, which supplies more than 70% of the world’s cocoa. Cocoa, which is made from the dried beans of the cacao tree, is the main ingredient in both dark and white chocolate.
Weather conditions have improved since then in Ivory Coast and Ghana, and cocoa production is increasing in Ecuador and other countries, according to an analysis by J.P. Morgan. The resulting supply increase is one reason cocoa prices are coming down.
But they’re also dropping because of lower global demand. Chocolate getting more expensive has turned off consumers, so manufacturers have cut the amount of chocolate they use or shifted to other products like gummy candies to keep prices in check, said Chris Costagli, a food thought leader at the market research company NIQ.
In the U.S., annual retail sales of chocolate rose 6.7% in 2025 compared to the prior year, largely because of price increases, according to NIQ data. But the number of individual products sold was down 1.3%, as consumers bought less chocolate overall.
The Trump administration’s tariffs were another reason U.S. chocolate prices increased last year.
The administration put a tariff averaging 15% on cocoa-producing countries last February, which raised the price of U.S. cocoa imports, according to the U.S. Federal Reserve.
In November, the administration removed tariffs on cocoa and other commodities that can’t be grown in the U.S., including coffee, spices and tropical fruit.
But tariffs of 15% or more on products from the European Union, including chocolates, remain in place.
Chocolates at a chocolate fair, in Brussels, Belgium, in 2017. File photo by Yves Herman/ Reuters
So far, declining cocoa prices haven’t necessarily let chocolate lovers pay less.
Costagli compares the situation to gas prices. Even when the cost of oil goes down, prices at the pump don’t immediately follow because companies need to use up the oil they bought at a higher price.
Chocolate makers like The Hershey Co. have long-term contracts that may require them to pay more than current cocoa prices. The market also is volatile; companies know that another bout of poor weather or a surge in demand could make cocoa prices surge again.
But Costagli said companies also watch shoppers’ reaction to prices.
“If the customer is still willing to pay that higher price point, do we really take the price down?” he said.
Mondelez International, which owns chocolate brands like Oreo, Cadbury and Toblerone, raised its prices by 8% globally in 2025 to counter higher cocoa costs.
In Europe, the company hiked prices by even more and saw a significant decrease in the amount of its products sold. As a result, Mondelez lowered prices this year in some markets, including the United Kingdom and Germany.
“We have learned that certain price points are very important, and so we have adjusted already to put our products at the right price point,” Mondelez Chairman and CEO Dirk Van de Put said during a February conference call with investors.
Van de Put said Mondelez didn’t plan immediate price cuts in North America, where both its price increases and its sales volume losses were more moderate.
Two segments of the chocolate market grew in the U.S. last year: value brands and super-premium brands, Costagli said.
The expanded interest in higher-end chocolate may seem surprising if consumers balked at paying more for a Snickers bar or a pack of Reese’s Peanut Butter Cups. But the companies behind super-premium lines like Ferrero Rocher, Justin’s and Lindt Excellence were less aggressive about instituting cocoa-related price increases since their products already were more expensive, Costagli said.
As mainstream chocolate makers like Hershey and Mars raised prices, some customers decided they’d just spend a little more, he said.
“It’s given the aspirational shopper that little push they need to trade up. If they wanted a better product, if they wanted better experience, better product characteristics, organic, fair trade, whatever it might be,” Costagli said.
On the flip side, value brands — think Whitman’s or some store-brand chocolates — also sold more products in the U.S. last year as price-conscious shoppers traded down from mainstream brands.
“The savings you get by trading down is actually greater than it used to be,” Costagli said. “So from an aspirational perspective, it’s easier to trade up, and from a financially insecure perspective, it saves you more to trade down.”
A free press is a cornerstone of a healthy democracy.
Support trusted journalism and civil dialogue.
APM Terminals, a subsidiary of A.P. Moller – Maersk (Maersk), and Eurogate aim for and are in advanced negotiations for a long-term partnership under which they plan to invest one billion Euro in the modernisation of their joint container terminal North Sea Terminal Bremerhaven (NTB).
The one billion Euro investment aims to upgrade NTB into one of the world’s most efficient and resilient container handling facilities, with zero greenhouse gas (GHG) emissions operations. The plan is to modernise the equipment and increase the terminal’s capacity from 3 to 4 million TEU throughput annually.
Through the electrification of equipment and the use of renewable electricity, the terminal is intended to operate with zero GHG emissions, the first of its kind in Germany. The planned investments remain subject to internal and external approvals.
“Bremerhaven has unique potential to grow as a strategic hub in the region and to support cargo flows into Germany as well as our ocean network. Our investments are intended to realise the full potential of the terminal, making NTB one of the most competitive terminals in Europe’s North Range. We aim to future-proof the terminal over the long term, while strengthening the reliability and resilience of supply chains for the German economy,” says Vincent Clerc, CEO of A.P. Moller – Maersk.
“With our NTB terminal we can proudly look back on more than 25 years of successful partnership with Maersk and APM Terminals and look forward to continuing this success story together in the future,” says Michael Blach, Chairman of the EUROGATE Group Management Board. “The joint project to equip the terminal with state-of-the-art technology and decarbonise the operations, thereby making NTB fit for the coming decades, shows how convinced we are of the future success of Bremerhaven as a location in the global maritime trade network. The modernisation of the NTB sets standards and also secures many high-value jobs in the region in the long term.”
“The fact that Maersk, a global market leader, is so strongly committed to Bremerhaven is impressive proof of the efficiency of our ports and of EUROGATE,” says Andreas Bovenschulte, Mayor of Bremen. “I very much welcome Maersk’s intention to expand and intensify its 25 years of successful cooperation at the Bremerhaven site. With Maersk’s announced investments in the port’s superstructure and the state and federal government’s investments in the port infrastructure, Bremerhaven will be well positioned for the future and its importance in the North Range will be strengthened. Now it is up to the federal government to press ahead with the deepening of the Outer Weser and implement it quickly.”
In addition to the investments, the deepening of the Outer Weser river is an essential prerequisite for fully unlocking the potential of the upgraded terminal. A corresponding planning process is currently underway at the level of the public administration.
Inflation rose just 0.2% in January from December and fell to 2.4% on an annual basis. Both readings were less than anticipated, in a positive sign for consumers.
Broadly, economists surveyed by Dow Jones expected inflation overall to have risen by 0.3% in January. On an annual basis, the expectation was that inflation would be tracking at 2.5%.
In recent months, as consumers face an affordability crisis, the Trump administration has rolled back tariffs on dozens of food items. The administration has also continued to reach trade deal frameworks with countries that it says will lead directly to lower tariffs.
The Bureau of Labor Statistics said that the price of housing “was the largest factor” in the increase for the month, rising 0.2%. The same went for the “food at home” category, which tracks grocery prices.
The price of energy was among the biggest drops in January, falling 1.5%.
Core inflation, which strips out volatile categories, was also right in line with expectations. That could help bolster the argument that recent rate cuts and actions by the administration are working to bring inflation under control after it soared to 3% in September last year.
There are some signs of significant tariff pass through to consumers, however, as many economists feared.
The price of laundry equipment and an index that tracks “other appliances” jumped 2.6% just from December to January.
Other indexes that rose sharply from month to month include those tracking the price of appliances overall, which rose 1.3%. Computers rose 3.1%, floor coverings jumped 3.2%, home furniture popped 1%, and boys’ apparel increased 2.4%.
The price of watches increased by 2.9% from month to month, and the reading that tracks video and audio equipment, including televisions, increased by 2.2%.
“You start to see some of the tariffs creep into some of the prices…and you see some sellers are deciding that they’re passing on those higher costs to consumers in the form of higher prices,” Amazon CEO Andy Jassy said on CNBC in mid-January. “I think you’re starting to see some more of that impact.”
Economists and analysts believe that companies may be nearing the end of pre-tariff priced products, which were made or imported before President Donald Trump’s sweeping tariffs went into effect last year.
But it wasn’t all bad news.
The price of eggs, a major source of consumer complaints last year, dropped another 7% in January from December. The price of beef and veal, which has seen a rise over recent months, also declined by 0.4%.
Friday’s report comes just two days after the delayed January jobs report, which looked positive for the month but included major revisions to recent hiring data that painted a gloomier picture.
Preliminary data had indicated that the U.S. economy added 584,000 jobs in 2025. But the Bureau of Labor Statistics revised the number down Wednesday to just 181,000 jobs.
The Federal Reserve has for months been balancing its two mandates — stable prices and full employment — on what some experts have described as a knife’s edge.
“Based on my forecast, we could be on hold for quite some time,” Federal Reserve Bank of Cleveland President Beth Hammack said Tuesday.
Hammack expects inflation to ease as the year progresses, but currently, she says, “inflation is still too high.”
Traders work at the New York Stock Exchange on Feb. 10, 2026.
NYSE
Stock futures were relatively unchanged on Friday, a day after a downbeat session for the U.S. stock market, as a key consumer inflation report failed to ignite a meaningful rally.
S&P 500 futures fell 0.1%, as did Nasdaq 100 futures. Futures tied to the Dow Jones Industrial Average were down 22 points, or 0.04%.
On Friday, the Bureau of Labor Statistics reported that the consumer price index — which measures the costs for goods and services in the U.S. economy — rose 0.2% in January, reflecting a gain of 2.4% on an annualized basis. The inflation gauge was expected to show a 0.3% increase on a month-over-month basis and a 2.5% advance from a year earlier, according to economists polled by Dow Jones.
When excluding volatile food and energy prices, core CPI came in line with expectations at 0.3% on the month and 2.5% year over year, however.
In early trading, semiconductor giant Applied Materials jumped 10% on the back of strong earnings results and encouraging outlook. Airbnb shares rose 5% as investors cheered the rental company’s upbeat guidance. Pinterest shares, by contrast, slipped 22% after the company posted fourth-quarter results that missed expectations and issued a weak forecast.
Major U.S. averages dropped on Thursday as fears around artificial intelligence disruption spread across the market, most notably into real estate, trucking and software sectors. The S&P 500 dropped nearly 1.6%, while the Nasdaq Composite lost about 2%. The Dow Jones Industrial Average shed almost 670 points, or 1.3%.
Each of the “Magnificent Seven” tech giants closed in the red. A 12% slide in Cisco Systems, driven by the company’s disappointing guidance, weighed on the broader market. Apple lost 5% during the regular session, notching its worst single-day loss since April 2025.
“In terms of an AI bubble, the reality is there’s some steam coming out of certain names as the market tries to determine winners and losers and is becoming more discriminate,” Brian Levitt, global market strategist at Invesco, said Thursday on CNBC’s “Closing Bell.”
“But the Dow Jones Industrial Average is close to 50,000. The S&P 500 is close to 6,900… There is, obviously, some carnage underneath, but in general, this is not an AI bubble. The markets are holding up very nicely,” he continued.
The three major averages are on pace for weekly losses, with the S&P 500 and Dow off more than 1% through Thursday’s close. The Nasdaq is on track for a 1.9% decline in the period.
BREZTRI AEROSPHERE® (budesonide, glycopyrrolate, and formoterol fumarate) Inhalation Aerosol
INDICATION
BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
LIMITATIONS OF USE
Not indicated for the relief of acute bronchospasm or for the treatment of asthma.
Please see full BREZTRI Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca products.
Notes
Asthma
Asthma is a prevalent, chronic respiratory disease affecting as many as 262 million people worldwide,2 including over 25 million in the US.3 When uncontrolled, inflammation and muscle tightening in the airway (bronchoconstriction) may cause wheezing, breathlessness, chest tightness, coughing, and even death.2,4 Many patients remain uncontrolled despite the availability of standard of care medicines and continue to experience significant limitations on lung function and reduced quality of life.5,6
KALOS and LOGOS Phase III trials
KALOS and LOGOS were replicate confirmatory, randomised, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to assess the efficacy and safety of BREZTRI Aerosphere (320/28.8/9.6μg and 320/14.4/9.6μg) compared with two fixed-dose, dual-combination therapies of budesonide, an ICS, and formoterol fumarate, a LABA: Symbicort pressurised metered-dose inhaler (pMDI) and PT009 (in an Aerosphere formulation).1,7,8 KALOS and LOGOS included approximately 4,300 randomised patients.
The trial design was optimised to evaluate the 320/28.8/9.6μg dose of BGF. The primary efficacy endpoints for the two individual trials were the change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 and trough FEV1 over 12-24 weeks and over 24 weeks.1,7,8 The primary endpoints and treatment comparisons in the KALOS and LOGOS trials differed according to regulatory submission approaches. The full results published in The Lancet Respiratory Medicine report the pooled analysis of KALOS and LOGOS results for BREZTRI compared with the ICS/LABA treatment groups combined, and includes comparisons of BREZTRI to individual comparators arms measured across both trials in the supplement.
In addition to the two registrational trials (KALOS and LOGOS), two qualifying trials, LITHOS and VATHOS, also met their primary endpoints.9,10 LITHOS and VATHOS included approximately 1,000 randomised patients.
BREZTRI/TRIXEO Aerosphere
Budesonide/glycopyrronium/formoterol fumarate (BGF), approved under the brand name BREZTRI Aerosphere in Japan, China and the US, and TRIXERO Aerosphere in the EU, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a LABA, glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), with budesonide, an ICS, and delivered via the Aerosphere pMDI. BREZTRI/TRIXEO Aerosphere (320/14.4/9.6μg) is approved to treat adults with COPD in more than 80 countries worldwide including the US, EU, China, Japan, and was prescribed to more than 5.5 million patients globally in 2024.11
AstraZeneca in Respiratory & Immunology
Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.
AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca’s website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.
Media Inquiries
|
Fiona Cookson |
+1 212 814 3923 |
|
|
US Media Mailbox: usmediateam@astrazeneca.com
References
1. Papi A, et al. Budesonide–glycopyrronium–formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. Lancet Respir. Med. 2026; https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00457-6/abstract [Last accessed: February 2026]
2. Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. [Last accessed: February 2026].
3. U.S. Centers for Disease Control and Prevention (CDC). Most Recent National Asthma Data. [Online]. Available at: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. [Last accessed: February 2026].
4. Fernandes AG, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014; 40 (4): 364-372.
5. Davis J, et al. Burden of asthma among patients adherent to ICS/LABA: A real-world study. J Asthma. 2019 Mar;56(3):332-340.
6. Buhl R, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respir Med. 2020 Feb: 162:105859.
7. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT04609878?limit=25&term=KALOS&rank=1. [Last accessed: February 2026].
8. Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT04609904?limit=25&term=LOGOS&rank=4 [Last accessed: February 2026].
9. Clinicaltrials.gov. A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT05755906?limit=25&term=LITHOS&rank=1. [Last accessed: February 2026].
10. Clinicaltrials.gov. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants with Inadequately Controlled Asthma (VATHOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT05202262?limit=25&term=VATHOS&rank=1. [Last accessed: February 2026].
11. AstraZeneca Data on File. 2025. REF-270910.
OSLO, Norway, Feb. 13, 2026 /PRNewswire/ — With reference to the announcement 13 February 07:00, Elkem clarifies certain aspects of the NOK 1 500 million underwritten equity issue.
The NOK 1 500 million underwritten equity issue will be conducted through a publicly announced bookbuilding process subject to market conditions and market terms, with a minimum application amount and allocation criteria to be decided by the Board. The Board will carefully consider the interests of all shareholders in relation to the equity capital raise, including in respect allocation of new shares. Elkem will subsequently conduct a repair offering providing shareholders the possibility to subscribe for new shares in the Company at the same subscription price.
This is the only equity issue that is contemplated in relation to the announcement made earlier today.
For further information, please contact:
Odd-Geir Lyngstad
VP Finance & Investor Relations
Tel: +47 976 72 806
Email: [email protected]
About Elkem:
Elkem is one of the world’s leading providers of advanced silicon-based materials shaping a better and more sustainable future. The company develops silicones, silicon products and carbon solutions by combining natural raw materials, renewable energy and human ingenuity. Elkem helps its customers create and improve essential innovations like electric mobility, digital communications, health and personal care as well as smarter and more sustainable cities. With a strong track record since 1904, its global team of more than 7 000 people has a joint commitment to stakeholders: Delivering your potential. In 2025, Elkem achieved an operating income of NOK 31 billion. Elkem has been awarded top score of A on Forests and Water Security, and B on Climate Change from CDP. Elkem is listed on the Oslo Stock Exchange (ticker: ELK), where the company is also included in the ESG Index. www.elkem.com
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/elkem/r/clarification-regarding-the-conditional-underwritten-equity-issue-in-elkem,c4307460
